Skip to Content
NIH - National Institutes of Health National Cancer Institute Division of Cancer Treatment and Diagnosis Center for Cancer Research
NCI Experimental Therapeutics Program (NExT)
Contact NExT
Show menu
Search this site
Last Updated: 09/25/14

Phase II NExT Projects

Applicant Institute Project
Choyke, Peter National Cancer Institute,
Center for Cancer Research, NIH
A Phase II Study of F-18 DCFBC, a Prostate Specific Membrane Antigen-Target
Diamond, Don Beckman Research Institute of the City of Hope CMV Peptide Vaccine to Protect Transplant Recipients Against CMV Infection
Davis, Thomas Celldex Therapeutics, Inc. Clinical Development of CDX-1401 Vaccine Regimen
Fleming, Alan GlaxoSmithKline Pharmaceuticals GSK2118436 BRAF Inhibitor
Frankel, Stanley Micromet, Inc Blinatumomab Clinical Development for B-lineage Malignancies
Frye, John Exelixis, Inc. XL184 (cabozantinib)
Graham, Martin Tetralogic Pharmaceuticals Corporation Predictive Biomarkers of SMAC-Mimetic (TL32711) Efficacy in Ovarian Cancer.
Hamdy, Ahmed Pharmacyclics PCI-32765, Btk Inhibitor for B-cell Malignancies
Johnson, Lisa Bristol-Myers Squibb Company BMS-936558 Anti-PD-1 Antibody Treatment of Cancer
Leigh, Bryan Tracon Pharmaceuticals Development of TRC102 as a Novel Inhibitor of Base Excision Repair
Leigh, Bryan Tracon Pharmaceuticals Development of TRC105 as a Novel Anti-angiogenic Monoclonal Antibody
Leopold, Lance Incyte Corporation INCB024360, A Novel Orally-Administered IDO 1 Inhibitor for Cancer Treatment
Levin, Jeremey GlaxoSmithKline Oral MEK Inhibitor GSK1120212
Quackenbush, Elizabeth Celldex Therapeutics, Inc. Continued Development of the Antibody-drug Conjugate CDX-011
Wagner, Anthony Amgen Incorporated Rilotumumab (AMG 102) NExT Application
Waldmann, Thomas National Cancer Institute,
Center for Cancer Research, NIH
Anti-IL-15 Receptor Antibody Therapy of Celiac Disease Associated Lymphoma
Wilson, Troy
(Klein, Pamela)
Intellikine, Inc. INK128 a TORC1/2 Inhibitor in Solid Tumors and Hematologic Malignancies